
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10134571/publications.pdf Version: 2024-02-01



RENKE MAAS

#	Article	IF	CITATIONS
1	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrology Dialysis Transplantation, 2007, 22, 801-806.	0.4	592
2	Pharmacokinetic and pharmacodynamic properties of oral Lâ€citrulline and Lâ€arginine: impact on nitric oxide metabolism. British Journal of Clinical Pharmacology, 2008, 65, 51-59.	1.1	403
3	Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community. Circulation, 2009, 119, 1592-1600.	1.6	310
4	Urinary 8-iso-Prostaglandin F 2α as a Risk Marker in Patients With Coronary Heart Disease. Circulation, 2004, 109, 843-848.	1.6	250
5	Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension. Journal of the American College of Cardiology, 2005, 46, 518-523.	1.2	239
6	Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 490-496.	3.0	235
7	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney International, 2002, 62, 339-345.	2.6	194
8	Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—An update on patient populations with a wide range of cardiovascular risk. Pharmacological Research, 2009, 60, 481-487.	3.1	186
9	The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vascular Medicine, 2002, 7, 213-225.	0.8	179
10	High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 211-219.	1.2	149
11	Suppression of paroxysmal atrial tachyarrhythmias ? results of the SOPAT trial. European Heart Journal, 2004, 25, 1395-1404.	1.0	147
12	Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress. Clinical Pharmacokinetics, 2003, 42, 437-459.	1.6	137
13	Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS ONE, 2016, 11, e0165811.	1.1	131
14	Liquid Chromatography–Tandem Mass Spectrometry Method for the Analysis of Asymmetric Dimethylarginine in Human Plasma. Clinical Chemistry, 2005, 51, 1268-1271.	1.5	115
15	Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis, 2010, 208, 518-523.	0.4	110
16	Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1714-1721.	2.2	98
17	Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism: Clinical and Experimental, 2006, 55, 1159-1164.	1.5	96
18	Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 435-441.	3.0	93

#	Article	IF	CITATIONS
19	Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. PLoS ONE, 2015, 10, e0136451.	1.1	92
20	Event-Recorder Monitoring in the Diagnosis of Atrial Fibrillation in Symptomatic Patients: Subanalysis of the SOPAT Trial. Journal of Cardiovascular Electrophysiology, 2006, 17, 1216-1220.	0.8	87
21	Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin. Journal of the American College of Cardiology, 2007, 49, 2274-2282.	1.2	84
22	Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. European Heart Journal, 2005, 26, 1846-1851.	1.0	81
23	N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction. European Journal of Clinical Pharmacology, 2015, 71, 85-94.	0.8	79
24	Asymmetric Dimethylarginine, Smoking, and Risk of Coronary Heart Disease in Apparently Healthy Men: Prospective Analysis from the Population-Based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and Experimental Data. Clinical Chemistry, 2007, 53, 693-701.	1.5	77
25	Association of Plasma ADMA Levels With MRI Markers of Vascular Brain Injury. Stroke, 2009, 40, 2959-2964.	1.0	77
26	Adverse Drug Events in Older Patients Admitted as an Emergency. Deutsches Ärzteblatt International, 2013, 110, 213-9.	0.6	73
27	A Randomized and Controlled Pilot Trial of beta-blockers for the Treatment of Recurrent Syncope in Patients with a Positive or Negative Response to Head-Up Tilt Test. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 816-821.	0.5	66
28	Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine. Antimicrobial Agents and Chemotherapy, 2011, 55, 3091-3098.	1.4	64
29	Reference Intervals for Plasma L-Arginine and the L-Arginine:Asymmetric Dimethylarginine Ratio in the Framingham Offspring Cohort. Journal of Nutrition, 2011, 141, 2186-2190.	1.3	63
30	Accuracy and Completeness of Drug Information in Wikipedia: A Comparison with Standard Textbooks of Pharmacology. PLoS ONE, 2014, 9, e106930.	1.1	63
31	Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vascular Medicine, 2005, 10, S49-S57.	0.8	61
32	Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. Atherosclerosis, 2009, 207, 541-545.	0.4	60
33	Diagnostic Yield of External Electrocardiographic Loop Recorders in Patients with Recurrent Syncope and Negative Tilt Table Test. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1837-1840.	0.5	59
34	Telmisartan Improves Endothelial Function in Patients With Essential Hypertension. Journal of Cardiovascular Pharmacology, 2007, 50, 367-371.	0.8	58
35	Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase. Circulation, 2011, 124, 2735-2745.	1.6	58
36	Stable isotope dilution assay for liquid chromatography–tandem mass spectrometric determination of l-homoarginine in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2294-2298.	1.2	57

#	Article	IF	CITATIONS
37	Dimethylarginine Dimethylaminohydrolase Overexpression Ameliorates Atherosclerosis in Apolipoprotein E-Deficient Mice by Lowering Asymmetric Dimethylarginine. American Journal of Pathology, 2010, 176, 2559-2570.	1.9	55
38	Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety, 2015, 24, 176-186.	0.9	55
39	Genome-Wide Association Study of <scp>l</scp> -Arginine and Dimethylarginines Reveals Novel Metabolic Pathway for Symmetric Dimethylarginine. Circulation: Cardiovascular Genetics, 2014, 7, 864-872.	5.1	53
40	Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). Journal of Molecular and Cellular Cardiology, 2012, 53, 392-400.	0.9	52
41	Asymmetrical Dimethylarginine Is Increased in Plasma and Decreased in Cerebrospinal Fluid of Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 58-64.	0.7	51
42	Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography–Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort. Clinical Chemistry, 2009, 55, 1539-1545.	1.5	51
43	The Role of Nitric Oxide Synthase Inhibition by Asymmetric Dimethylarginine in the Pathophysiology of Preeclampsia. Gynecologic and Obstetric Investigation, 2010, 69, 1-13.	0.7	51
44	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.4	50
45	Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLoS ONE, 2017, 12, e0171353.	1.1	50
46	Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. International Journal of Cardiology, 2007, 122, 176-178.	0.8	47
47	Plasma Concentrations of Asymmetric Dimethylarginine (ADMA) in Colombian Women With Pre-eclampsia. JAMA - Journal of the American Medical Association, 2004, 291, 823-824.	3.8	46
48	Acute effects of various fast-food meals on vascular function and cardiovascular disease risk markers: the Hamburg Burger Trial. American Journal of Clinical Nutrition, 2007, 86, 334-340.	2.2	46
49	Simultaneous Assessment of Endothelial Function, Nitric Oxide Synthase Activity, Nitric Oxide–Mediated Signaling, and Oxidative Stress in Individuals with and without Hypercholesterolemia. Clinical Chemistry, 2008, 54, 292-300.	1.5	45
50	Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA With Carotid Artery Intimal Media Thickness in the Framingham Heart Study Offspring Cohort. Stroke, 2009, 40, 2715-2719.	1.0	44
51	Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients. PLoS ONE, 2016, 11, e0155649.	1.1	42
52	Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1). Amino Acids, 2013, 45, 989-1002.	1.2	41
53	Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis, 2007, 191, 211-219.	0.4	39
54	The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents. Journal of Clinical Oncology, 2021, 39, 1983-1994.	0.8	37

#	Article	IF	CITATIONS
55	Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Critical Care Medicine, 2007, 35, 1876-1881.	0.4	36
56	In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice. Biochemical and Biophysical Research Communications, 2013, 430, 84-89.	1.0	36
57	Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients. PLoS ONE, 2013, 8, e72694.	1.1	35
58	Alanine-glyoxylate aminotransferase 2 (AGXT2) Polymorphisms Have Considerable Impact on Methylarginine and β-aminoisobutyrate Metabolism in Healthy Volunteers. PLoS ONE, 2014, 9, e88544.	1.1	33
59	Elevation of Asymmetrical Dimethylarginine (ADMA) and Coronary Artery Disease in Men with Erectile Dysfunction. European Urology, 2005, 48, 1004-1012.	0.9	29
60	A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 220-228.	1.2	28
61	P2Y12polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. British Journal of Clinical Pharmacology, 2008, 65, 540-547.	1.1	28
62	Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1907-10.	1.4	28
63	Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacological Research, 2009, 60, 488-493.	3.1	27
64	A Novel Pathway for Metabolism of the Cardiovascular Risk Factor Homoarginine by alanine:glyoxylate aminotransferase 2. Scientific Reports, 2016, 6, 35277.	1.6	27
65	The prognostic biomarker L-homoarginine is a substrate of the cationic amino acid transporters CAT1, CAT2A and CAT2B. Scientific Reports, 2017, 7, 4767.	1.6	27
66	Plasma Nitrate and Incidence of Cardiovascular Disease and All ause Mortality in the Community: The Framingham Offspring Study. Journal of the American Heart Association, 2017, 6, .	1.6	26
67	Comparative evaluation of different medication safety measures for the emergency department: physicians' usage and acceptance of training, poster, checklist and computerized decision support. BMC Medical Informatics and Decision Making, 2013, 13, 79.	1.5	25
68	Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort. Clinical Chemistry and Laboratory Medicine, 2020, 58, 733-740.	1.4	24
69	Implementation of Warnings From Dear Doctor Letters (Rote-Hand-Briefe). Deutsches Ärzteblatt International, 2014, 111, 255-63.	0.6	23
70	Predicting Recurrence of Vasovagal Syncope: A Simple Risk Score for the Clinical Routine. Journal of Cardiovascular Electrophysiology, 2009, 20, 416-421.	0.8	22
71	Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy. Nephrology Dialysis Transplantation, 2014, 29, 2035-2042.	0.4	22
72	Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients. British Journal of Clinical Pharmacology, 2007, 63, 672-679.	1.1	21

#	Article	IF	CITATIONS
73	Transport of L-Arginine Related Cardiovascular Risk Markers. Journal of Clinical Medicine, 2020, 9, 3975.	1.0	21
74	Pharmacokinetics of Oral Doses of Telmisartan and Nisoldipine, Given Alone and in Combination, in Patients With Essential Hypertension. Journal of Clinical Pharmacology, 2007, 47, 295-304.	1.0	20
75	Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics. European Journal of Clinical Pharmacology, 2013, 69, 975-984.	0.8	20
76	Diabetes-linked transcription factor HNF4α regulates metabolism of endogenous methylarginines and β-aminoisobutyric acid by controlling expression of alanine-glyoxylate aminotransferase 2. Scientific Reports, 2016, 6, 35503.	1.6	20
77	Correlation of Biomarkers of Endothelium Dysfunction and Matrix Remodeling in Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 984-988.	1.0	19
78	Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases. Current Pharmaceutical Design, 2014, 20, 3530-3547.	0.9	19
79	Different indications, warnings and precautions, and contraindications for the same drug—an international comparison of prescribing information for commonly used psychiatric drugs. Pharmacoepidemiology and Drug Safety, 2013, 22, 329-333.	0.9	18
80	Application of the Pareto principle to identify and address drug-therapy safety issues. European Journal of Clinical Pharmacology, 2014, 70, 727-736.	0.8	17
81	The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine. PLoS ONE, 2019, 14, e0213747.	1.1	17
82	Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. Journal of Nephrology, 2012, 25, 1016-1022.	0.9	17
83	Antihypertensive therapy: special focus on drug interactions. Expert Opinion on Drug Safety, 2003, 2, 549-579.	1.0	16
84	A new approach to identify, classify and count drugâ€related events. British Journal of Clinical Pharmacology, 2013, 76, 56-68.	1.1	16
85	A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. Free Radical Biology and Medicine, 2009, 47, 1584-1590.	1.3	15
86	l-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma triglycerides. Nutrition Research, 2009, 29, 291-297.	1.3	15
87	ADMA and the role of the genes: Lessons from genetically modified animals and human gene polymorphisms. Pharmacological Research, 2009, 60, 475-480.	3.1	15
88	Extensive characterization of the human DDAH1 transgenic mice. Pharmacological Research, 2009, 60, 494-502.	3.1	15
89	Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. American Journal of Hypertension, 2005, 18, 1549-1555.	1.0	14
90	Medication safety and knowledgeâ€based functions: a stepwise approach against information overload. British Journal of Clinical Pharmacology, 2013, 76, 14-24.	1.1	14

#	Article	IF	CITATIONS
91	Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list. BMC Health Services Research, 2016, 16, 109.	0.9	14
92	Plasma asymmetric dimethylarginine, l-arginine and left ventricular structure and function in a community-based sample. Atherosclerosis, 2009, 204, 282-287.	0.4	12
93	Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. American Heart Journal, 2016, 176, 100-106.	1.2	11
94	Kidney and liver are the main organs of expression of a key metabolic enzyme alanine:glyoxylate aminotransferase 2 in humans. Atherosclerosis Supplements, 2019, 40, 106-112.	1.2	11
95	Effect of Syncope-Related Traumatic Injuries on the Diagnostic Evaluation and Syncope Recurrence of Patients With Syncope and Apparently Normal Hearts. American Journal of Cardiology, 2005, 95, 1101-1103.	0.7	9
96	An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. American Journal of Hypertension, 2007, 20, 758-763.	1.0	9
97	Dental procedures in patients treated with antiplatelet or oral anticoagulation therapy – an anonymous survey. Gerodontology, 2016, 33, 447-452.	0.8	9
98	Building the technical infrastructure to support a study on drug safety in a general hospital. Studies in Health Technology and Informatics, 2011, 169, 325-9.	0.2	9
99	An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma. Cancers, 2021, 13, 6329.	1.7	9
100	Development of a Standardized Rating Tool for Drug Alerts to Reduce Information Overload. Methods of Information in Medicine, 2016, 55, 507-515.	0.7	8
101	Data Requirements for the Correct Identification of Medication Errors and Adverse Drug Events in Patients Presenting at an Emergency Department. Methods of Information in Medicine, 2017, 56, 276-282.	0.7	7
102	Establishment of reference values for the lysine acetylation marker NÉ›-acetyllysine in small volume human plasma samples by a multi-target LC–MS/MS method. Amino Acids, 2019, 51, 1259-1271.	1.2	7
103	Effect of Lowering Asymmetric Dimethylarginine (ADMA) on Vascular Pathology in Atherosclerotic ApoE-Deficient Mice with Reduced Renal Mass. International Journal of Molecular Sciences, 2014, 15, 5522-5535.	1.8	5
104	Vectorial transport of the arginine derivatives asymmetric dimethylarginine (ADMA) and l-homoarginine by OATP4C1 and P-glycoprotein studied in double-transfected MDCK cells. Amino Acids, 2020, 52, 975-985.	1.2	5
105	The CredibleMeds $\hat{A}^{\otimes}$ list: usage of QT interval prolonging drugs in Germany and discordances with prescribing information. British Journal of Clinical Pharmacology, 2021, , .	1.1	5
106	Drugs linked to plasma homoarginine in chronic kidney disease patients—a cross-sectional analysis of the German Chronic Kidney Disease cohort. Nephrology Dialysis Transplantation, 2020, 35, 1187-1195.	0.4	4
107	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular Diabetology, 2022, 21, 4.	2.7	4
108	Asymmetric dimethylarginine predicts outcome and time of stay in hospital in patients attending an internal medicine emergency room. Clinica Chimica Acta, 2009, 401, 20-24.	0.5	3

#	Article	IF	CITATIONS
109	Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary ArteryÂDisease. Journal of the American College of Cardiology, 2021, 77, 1551-1553.	1.2	3
110	The effect object paradigma means to support medication safety with clinical decision support. Studies in Health Technology and Informatics, 2014, 205, 1065-9.	0.2	3
111	Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications—A Systematic Analysis of SmPCs/PI of Major Drug Markets. Journal of Clinical Medicine, 2022, 11, 1933.	1.0	3
112	Screening of commonly prescribed drugs for effects on the CAT1-mediated transport of l-arginine and arginine derivatives. Amino Acids, 2022, 54, 1101-1108.	1.2	2
113	L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact. Metabolites, 2022, 12, 273.	1.3	2
114	Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study. PLoS ONE, 2021, 16, e0254577.	1.1	1